TTPH Tetraphase Pharmaceuticals Inc.

1.22
+0.04  (+3%)
Previous Close 1.18
Open 1.25
Price To Book 0.38
Market Cap 8,856,268
Shares 7,259,236
Volume 126,601
Short Ratio
Av. Daily Volume 200,355
Stock charts supplied by TradingView

NewsSee all news

  1. Tetraphase Pharmaceuticals and AcelRx Pharmaceuticals Enter into Definitive Merger Agreement

    AcelRx to Acquire Tetraphase in an all-stock transaction Tetraphase equity holders to own 14.6% of the combined company and receive Contingent Value Rights worth up to $12.5 Million Acquisition Expected to Close in

  2. Tetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results and Highlights Achievements and Key 2020 Milestones

    XERAVA Carton Sales Grew over 45% Compared with the Third Quarter of 2019 XERAVA is on formulary or available at 1,200 Institutions Increased Formulary Uptake, with a 99% Success Rate for all Formulary Reviews to

  3. Tetraphase Pharmaceuticals Announces $17.5 Million of Financings Priced At-the-Market

    Proceeds Will Fund the Commercialization of XERAVA Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to

  4. Tetraphase Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate Developments

    XERAVA™ Carton Sales Grew over 30% Compared with Second Quarter of 2019 Increased Formulary Uptake, with a 99% Success Rate for all Formulary Reviews to Date -Company to Hold Conference Call Today at 4:30 PM

  5. Tetraphase Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call

    Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced that company management will

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial did not meet endpoints September 2015. Additional Phase 3 trial also did not meet primary endpoints - noted February 13, 2018.
Eravacycline (TP-434) - IGNITE3
cUTI - complicated urinary tract infections
FDA approval announced August 27, 2018.
Eravacycline (TP-434) - IGNITE4
cIAI (complicated intra-abdominal infections)
Phase 1 trial complete.
TP-271
Community-acquired bacterial pneumonia (CABP)
Phase 2 ready.
TP-6076

Latest News

  1. Tetraphase Pharmaceuticals and AcelRx Pharmaceuticals Enter into Definitive Merger Agreement

    AcelRx to Acquire Tetraphase in an all-stock transaction Tetraphase equity holders to own 14.6% of the combined company and receive Contingent Value Rights worth up to $12.5 Million Acquisition Expected to Close in

  2. Tetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results and Highlights Achievements and Key 2020 Milestones

    XERAVA Carton Sales Grew over 45% Compared with the Third Quarter of 2019 XERAVA is on formulary or available at 1,200 Institutions Increased Formulary Uptake, with a 99% Success Rate for all Formulary Reviews to

  3. Tetraphase Pharmaceuticals Announces $17.5 Million of Financings Priced At-the-Market

    Proceeds Will Fund the Commercialization of XERAVA Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to

  4. Tetraphase Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate Developments

    XERAVA™ Carton Sales Grew over 30% Compared with Second Quarter of 2019 Increased Formulary Uptake, with a 99% Success Rate for all Formulary Reviews to Date -Company to Hold Conference Call Today at 4:30 PM

  5. Tetraphase Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call

    Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced that company management will

  6. Tetraphase Pharmaceuticals Announces Completion of $8 Million Registered Direct Offering Priced At-the-Market

      Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ (eravacycline for injection) to treat serious and life-threatening infections,

  7. Tetraphase Pharmaceuticals Announces $8 Million Registered Direct Offering Priced At-the-Market

    Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, today

  8. Tetraphase Pharmaceuticals Announces Reverse Stock Split

    Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections,

  9. Tetraphase Pharmaceuticals to Present XERAVA™ (Eravacycline) Data at IDWeek 2019

    – Seven Abstracts Selected for Poster Presentations – Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ (eravacycline for injection)

  10. Tetraphase Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

    Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, today